Brought to you by 
AstraZeneca, Pozen co-develop chronic pain treatment; US rights sublicensed to Horizon
21 Jan 2016
Executive Summary
Pain therapeutics company Pozen and AstraZeneca have teamed up to develop a fixed-dose tablet combining the non-steroidal anti-inflammatory (NSAID) drug naproxen with the proton pump inhibitor esomeprazole to treat chronic pain and inflammation in patients at risk for developing NSAID-related gastric ulcers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com